Follow us on Twitter
twitter icon@FreshPatents


Overweight patents

      

This page is updated frequently with new Overweight-related patent applications.




 Aircraft landing emergency carriage patent thumbnailAircraft landing emergency carriage
A method of landing an aircraft which is overweight or whose landing wheels are not operatively deployed, including: providing a carriage assembly which may travel along a landing path at the landing speed of the aircraft; providing braking means capable of decelerating the carriage assembly supporting an aircraft to a manoeuvrable speed within the length of the landing strip; operatively positioning the carriage assembly for receiving an aircraft at the end of its flight path; flying the aircraft onto the operatively positioned carriage assembly; and operating the braking means to reduce the speed of the carriage assembly supporting the aircraft.. .

 Maternal vitamin b2 administration for the prevention of increased adiposity, overweight or obesity in the offspring patent thumbnailMaternal vitamin b2 administration for the prevention of increased adiposity, overweight or obesity in the offspring
The present invention generally relates to the early prevention of overweight, obesity, excessive fat accumulation and/or associated metabolic disorders in infants or children. For example, the present invention relates to the prevention of overweight, obesity, excessive fat accumulation and/or associated metabolic disorders in infants or children through appropriate maternal nutrition for women desiring to get pregnant and/or during pregnancy and/or lactation.
Nestec S.a.


 Antagonists of slc38a9 and their use in therapy patent thumbnailAntagonists of slc38a9 and their use in therapy
The present invention relates to an antagonist or modulator of slc38a9 for use in treating a disease associated with mtorc1 activation, like a proliferative disease (e.g. A cancerous disease or benign proliferative disease), a metabolic disorder, a disorder of the immune system, a disorder causing premature aging, an ophthalmic disorder or a neurological disorder.
Cemm - Forschungzentrum Fuer Molekulare Medizin Gmbh


 Support apparatus patent thumbnailSupport apparatus
The present disclosure provides a support for people with distended abdominal areas such as, but not limited to, individuals who are overweight or pregnant. Further, the support apparatus may be used by people suffering from back problems, as the raised area surrounding the opening in the support raises the pelvis and is intended to remove pressure from the lumbar spine and other areas of a person's midsection..

 Activated soy pod fiber patent thumbnailActivated soy pod fiber
The present disclosure encompasses, among other things, compositions and methods of enhancing glyceollin content of soybean tissue as well as methods of large-scale production of soybean tissues comprising elevated glyceollin content. The present disclosure further encompasses administration of food products comprising glyceollins in the treatment or prevention (i.e., delay of onset) of overweight, obesity, prediabetes, diabetes, ibd, and gastrointestinal dysbiosis..
Microblome Therapeutics Llc


 Methods of treating an overweight or obese subject patent thumbnailMethods of treating an overweight or obese subject
The invention herein generally relates to pharmaceutical formulations and methods of treating an overweight or obese subject, and overweight- or obesity-related conditions.. .
Zafgen, Inc.


 Oxaspiro[2.5]octane derivatives and analogs patent thumbnailOxaspiro[2.5]octane derivatives and analogs
The invention provides oxaspiro[2.5]octane derivatives and analogs, methods for preparation thereof, intermediates thereto, pharmaceutical compositions, and uses thereof in the treatment of various disorders and conditions, such as overweight and obesity.. .
Zafgen, Inc.


 Fat removal device and obesity treatment patent thumbnailFat removal device and obesity treatment
A medical device for treatment for overweight or obesity is presented. The medical device is attached or implanted in patient's target body organs, wherein in each one of the device attachments, or daily in the case of long continuous attachment, the device removes up to 100 grams of energy containing materials from the body.

 Implantable prosthetic device for weight loss in an obese or overweight patient comprising an inflatable gastric balloon and a duodenal prosthesis patent thumbnailImplantable prosthetic device for weight loss in an obese or overweight patient comprising an inflatable gastric balloon and a duodenal prosthesis
According to the invention, such a device is characterized in that it comprises a system for coupling said balloon to said duodenal prosthesis; said duodenal prosthesis is compressible and expandable in a radial direction; said prosthesis has a wall that is fixedly attached, on at least one part of its length, to a helical frame and said helix has an irregular pitch.. .

 Nutritional compositions with phospholipids patent thumbnailNutritional compositions with phospholipids
The present invention relates to a nutritional composition such as an infant formula comprising phospholipids in an amount of at least 300 mg/l. Bioactive compounds may preferably be added to the nutritional composition.
Nestec S.a.


System and method to estimate reduction of lifetime healthcare costs based on body mass index

An on-demand and real-time evidence based cost modeling and predictive analysis system, and a financial incentives based plan to reduce healthcare costs. An analytics system that includes a data aggregator and regression models generates incremental expenditures among overweight and obese individuals, predictive forecasts of future medical costs, and predictive forecasts of cost reduction based on financial incentives to recipients.

Compositions comprising eno1 and their use in methods of treating obesity or overweight and reducing weight gain

The invention provides a method for reducing or preventing body weight gain in a subject comprising administering to the subject enolase 1 (eno1). The invention also provides methods of treating obesity, and of reducing body weight in a subject afflicted with an overweight condition, comprising administering to the subject enolase 1 (eno1).
Berg Llc

Use of compositions comprising bifidobacterium animalis ssp. lactis lmg p-28149

A composition made from at least one probiotic for the use of same in the curative treatment of body weight gain in an overweight human and/or in the preventive treatment of body weight gain in a human who is overweight or has been overweight, said probiotic being bifidobacterium animalis ssp. Iactis n° lmg p-28149..
Vesale Pharma Sa

Methods and compositions for using cinnamaldehyde and zinc for weight management

Compositions comprise an amount of cinnamaldehyde that is orally tolerable, thus avoiding an unpleasant mouth feeling, and also tolerable in the gastrointestinal tract. The amount of cinnamaldehyde is supplemented by zinc, and the combination is effective to increase at least one of energy expenditure, sympathetic nervous system activity, or fat oxidation, relative to a composition lacking cinnamaldehyde and zinc but otherwise identical.
Nestec S.a.

Maternal vitamin b6 administration for the prevention of increased adiposity, overweight or obesity in the offspring

The present invention generally relates to the early prevention of overweight, obesity, excessive fat accumulation and/or associated metabolic disorders in infants or children. For example, the present invention relates to the prevention of overweight, obesity, excessive fat accumulation and/or associated metabolic disorders in infants or children through appropriate nutrition for women desiring to get pregnant and/or during pregnancy and/or lactation.
Nestec S.a.

Ingestible formulations for transient, noninvasive reduction of gastric volume

Provided are ingestible polymeric formulations and oral dosage forms for the reduction of gastric volume in the treatment of overweight and obese patients. The formulation includes an acid-sensitive, gelatin coating over a dehydrated hydrophilic polymer.

Maternal vitamin b12 administration for the prevention of increased adiposity, overweight or obesity in the offspring especially offspring overweight and/or obese mothers

The present invention generally relates to the early prevention of overweight, obesity, excessive fat accumulation and/or associated metabolic disorders in infants or children. For example, the present invention relates to the prevention of overweight, obesity, excessive fat accumulation and/or associated metabolic disorders in infants or children through appropriate nutrition for women desiring to get pregnant and/or during pregnancy and/or lactation.
Nestec S.a.

Compositions and methods for reducing major adverse cardiovascular events

The present application relates to compositions, kits, uses, systems and methods of using naltrexone and bupropion, or pharmaceutically acceptable salts thereof, for reducing the risk of adverse cardiovascular outcomes or events, including major adverse cardiovascular events (mace) in subjects, preferably those at increased risk of adverse cardiovascular outcomes or mace, that may be overweight or obese. The present application also relates to compositions, kits, uses, systems and methods of using naltrexone and bupropion or pharmaceutically acceptable salts thereof for treatment of overweight or obesity in subjects, preferably at increased risk of adverse cardiovascular outcomes or mace, wherein the treatment reduces the risk of mace..
Orexigen Therapeutics, Inc.

Brown adipocyte progenitors in human skeletal muscle

Brown adipose tissue (“bat”) progenitor cells and methods for identifying bat progenitor cells in a population of cells are provided. Methods are also provided for inducing differentiation of bat progenitor cells into differentiated brown adipocytes, inducing expression or increased activity levels of bat uncoupling protein-1 (“ucp1”), and for identifying agents capable of inducing differentiation of bat progenitor cells into brown adipocytes and/or inducing expression or increased activity levels of ucp1.
Energesis Pharmaceuticals, Inc.

Methods and compositions for increasing energy expenditure using cinnamaldehyde

Compositions comprise an amount of cinnamaldehyde that is orally tolerable, thus avoiding an unpleasant mouth feeling, and also tolerable in the gastrointestinal tract. The amount of cinnamaldehyde is effective to increase at least one of energy expenditure, sympathetic nervous system activity, or fat oxidation, relative to a composition lacking cinnamaldehyde but otherwise identical.
Nestec S.a.

Use of nutritional compositions having a low protein amount

The present invention relates to the use of a nutritional composition having a low amount of protein, such as less than 1.8 g/100 kcal for administration to infants of non-obese and non-overweight mothers so as to reduce the risk of developing metabolic syndrome, increased weight gain, increased fat deposition, overweight, obesity, insulin resistance, glucose intolerance or diabetes mellitus later in said infant's life.. .
Nestec S.a

Ucp1 (thermogenin) - inducing agents for use in the treatment of a disorder of the energy homeostasis

The present invention relates to compositions comprising an agent, like a polynucleotide, which induces or upregulates expression of ucp1 for use in treating or preventing a disorder of the energy homeostasis, overweight, adiposity, obesity, metabolic syndrome or related diseases or disorders in a subject. The present invention also relates to a method of treating or preventing a disorder of the energy homeostasis, overweight, adiposity, obesity, metabolic syndrome or related diseases or disorders in a subject comprising administrating a composition comprising a polynucleotide which induces or upregulates expression of ucp1..
L'université Nice Sophia Antipolis

Synthetic composition for preventing or treating cvd

The invention relates to hmos and compositions comprising thereof for reducing the risk of, preventing, or treating cvd and/or cdv associated pathological conditions or diseases in humans, particularly in overweight and obese humans.. .
Glycom A/s

Method of reducing employer health related costs while promoting employee wellness and health benefit plan strategy for same

In an effort to reduce employer health insurance related costs, at least one benefit under a health benefit plan is conditional on the employee voluntarily participating in a wellness program. The wellness program could include wellness categories such as a tobacco free category, normal blood pressure category, regular exercise category, a non-overweight category, a healthy cholesterol level category, a healthy blood glucose level category, and possibly even a category for participation in a health risk assessment.

Methods and device arrangement for physical activity thresholds promoting fat and cholesterol metabolism in high risk subjects

Method and device determine the threshold values for the volume and intensity of physical activity or the lowest levels that reduce risk factors in persons who suffer from disorders of sugar and lipid metabolism and are overweight. The method characterized in that the device registers a person's daily physical activity, compares it with the measured threshold levels and informs by its own or outside screen, if the volume and/or intensity of the physical activity has been sufficient to prevent the effects of disease risk factors.

Methods for predicting overweight risk for pets and adult percent body fat

The invention provides methods for determining overweight risk in a companion animal and to predict percent body fat in a young animal upon maturity. In one embodiment, a method for determining overweight risk in a companion animal can comprise measuring a relative abundance of bacteria from a microbiome of the companion animal; comparing the relative abundance of the bacteria to a relative abundance of the bacteria in a lean microbiome profile or in an overweight microbiome profile; and determining that the companion animal is at risk for being overweight if the relative abundance of bacteria is within the overweight microbiome profile or if the relative abundance of bacteria is outside the lean microbiome profile..
Nestec Sa

Inhibitors of diacylglycerol o-acyltransferase 1 (dgat-1) and uses thereof

The invention pertains to the use of fused bicyclo heterocyclic adducts of thiohydroxy pyridines or pyrimidines as diacylglycerol o-acyltransferase 1 (dgat-1) inhibitors to treat hyperlipidiemias and various diseases and disorders associated therewith. Other conditions also can be ameliorated or avoided, such as high postprandial triglycerides or diet-related hypertriglyceridemia, cardiovascular risk associated with excessive triglycerides, and insulin resistance/glucose intolerance in overweight patients, those with diabetes or other glucose metabolic disorders such as syndrome x and/or polycystic ovary disease..
Metabasis Therapeutics, Inc.

Nutrition-balancing containers and use

A four step system for weight loss in a person who is overweight or obese by introducing protein, vegetable, and starch (carbohydrate) in specific ratios to promote fat utilization and weight loss from fat composition of the person's entire body. The system utilizes portion control meal plates for weight loss in an overweight or obese person that have different protein, vegetable, and starch (carbohydrate) intake portions..

Treatment of obesity using non-daily administration of 6-o-(4-dimethylaminoethoxy) cinnamoyl fumagillol

The invention generally relates to methods of treating an overweight or obese subject, and treating overweight- or obesity-related conditions using non-daily administration of, e.g., a metap-2 inhibitor.. .
Zafgen, Inc.

Balanced rotating component for a gas powered engine

A rotating component for a turbine engine includes a rotor portion protruding radially outward, at least one overweight region is located in the rotor portion, and at least one additively manufactured counterweight region is positioned relative to the at least one overweight region such that the rotating component is circumferentially balanced.. .
United Technologies Corporation

Compositions capable of enhancing thermogenesis and uses thereof

The present invention refers to novel compositions and to methods of using the compositions to treat and/or prevent obesity, obesity-related diseases or disorders (e.g., hyperglycemia, hyperinsulinemia, elevated hemoglobin a1c (hba1c), diabetes, or cardiovascular disease), and overweight. This invention also generally relates to compositions and to methods of using the compositions to increase basal metabolic rate..
Specialty Nutrition Group, Inc.

Method for producing hydrogels coupling high elastic modulus and absorbance

The present invention provides crosslinked carboxymethylcellulose having high elastic modulus coupled with high absorbance capacity when swollen in simulated gastric fluid/water (1:8) and simulated intestinal fluids. The invention further provides methods of making the crosslinked carboxymethylcellulose, compositions comprising the crosslinked carboxymethylcellulose and methods of using the crosslinked carboxymethylcellulose, for example, for treating overweight or obesity or for enhancing glycemic control..
Gelesis, Llc

Engineered polypeptides having enhanced duration of action and reduced immunogenicity

Compounds are provided having inter alia good duration of action, high potency and/or convenient dosing regimens including once weekly administration. The compounds are engineered polypeptides which incorporate an albumin binding domain in combination with one or more biologically active polypeptides.

System and evidence based differential analysis and incentives based healthcare policy

An on-demand and real-time evidence based cost modeling and predictive analysis system, and a financial incentives based plan to reduce healthcare costs. An analytics system that includes a data aggregator and regression models generates incremental expenditures among overweight and obese individuals, predictive forecasts of future medical costs, and predictive forecasts of cost reduction based on financial incentives to recipients.

Eletric bicycle and control method thereof

An electric bicycle and a method of controlling the same are disclosed. The electric bicycle according to one embodiment of the present invention includes a weight sensing unit for sensing a rider's weight; a motor output controlling unit for controlling a motor driving output; and an electronic control unit for varying the motor output through the motor output controlling unit according to the weight sensed by the weight sensing unit, and the weight sensing unit classifies the rider's weight into a standard weight mode, an underweight mode, and an overweight mode according to the sensed weight, and if the weight is in the underweight mode, the weight sensing unit reduces the motor output to a value below the motor output for the standard weight mode and if the weight is in the overweight mode, the weight sensing unit increases the motor output to a value above the motor output for the standard weight mode..
Mando Corporation

Methods and compositions for preserving lean body mass and promoting fat loss during weight loss

The invention provides compositions and methods for preserving lean body mass and promoting fat loss during weight loss. The methods comprise identifying an animal that is obese or overweight and administering to the animal a food composition in an amount less than the animal's baseline maintenance energy requirement (mer), the food composition comprising from about 30% to about 65% protein, from about 10% to about 20% carbohydrate, and from about 10% to about 25% fat; where the protein and carbohydrate are in a ratio effective for preserving lean body mass and promoting fat loss during administration of the food composition to the animal..
Nestec Sa

Microrna and uses in brown fat differentiation

This invention reveals a novel mirna and a novel mirna-regulated signaling network which controls brown adipogenesis and thermogenic programs, thereby providing a powerful approach for the treatment of obesity and related metabolic diseases. In this regard, the present invention is also directed towards methods of treatment of obesity and excess weight (overweight) and metabolic disorders caused by or aggravated by a subject being overweight or obese..
Joslin Diabetes Center, Inc.

Engineered polypeptides having enhanced duration of action

Compounds are provided having inter alia good duration of action, high potency and/or convenient dosing regimens including once weekly administration. The compounds are engineered polypeptides which incorporate an albumin binding domain in combination with one or more biologically active polypeptides.
Aegerion Pharmaceuticals, Inc.

Muscle preservation in overweight or obese adult during weight loss program

The invention pertains to the use of a composition comprising per serving between 50-300 kcal; between 10 g and 35 g proteinaceous matter; and at least 2.5 microgram vitamin d, for the manufacture of a nutritional product for (a) the treatment or prevention of muscle mass decrease, (b) stimulation of muscle mass increase; or (d) stimulating muscle mass preservation, in obese or overweight adults of at least 40 years of age participating in a weight loss program. The inventors surprisingly found that nutritional supplementation with a low-caloric composition rich in protein, particularly whey protein and leucine, compared to an iso-caloric control supplement without protein, synergistically leads to preservation of muscle mass during a weight loss program involving a hypocaloric diet and a resistance exercise program in overweight/obese older adult..
N.v. Nutricia

Use of vitamin k for weight maintenance and weight control

Vitamin k is effective in counteracting (1) increase of body weight and body mass index (bmi), (2) accumulation of body fat mass and (3) accelerates weight loss during calory restriction or other life style interventions aiming weight reduction. A pharmaceutical composition or nutritional formulation comprising vitamin k is provided which can be used to combat overweight or obesity, either as a single, dedicated product or in combination with other slimming products or life style changes..
Vitak B.v.

Lachnospiraceae in the gut microbiota and association with body weight

The present invention relates to means and methods for modulating the gut microbiota composition of a subject, preferably a human. In particular, the present invention provides an agent capable of reducing the proportion of lachnospiraceae in the gut microbiota composition of a subject which agent is useful for promoting weight loss or preventing weight gain in a subject, preferably an obese or overweight subject.
Nestec S.a.

Highly soluble leptins

The disclosure provides chimeric polypeptides and nucleic acid molecules encoding chimeric polypeptides. Also provided are pharmaceutical compositions and methods of treatment for diseases and disorders including lipodystrophy, dyslipidemia, hyperlipidemia, overweight, obesity, hypothalamic amenorrhea, alzheimer's disease, leptin deficiency, fatty liver disease or diabetes (including type i and type ii).
Aegerion Pharmaceuticals, Inc.

Myo-inositol trispyrophosphate as an anti-obesity agent

The present invention provides for novel treatments of obesity and overweight and related disorders. The invention provides, in part, method of treatment comprising, or uses of inositol-tripyrophosphate (itpp) in these disease states..
Normoxys, Inc.

Methods of treating infections in overweight and obese patients using antibiotics

The present disclosure relates generally to methods of treating infections in overweight or obese patients using antibiotics. According to statistics compiled by national health and nutrition examination survey conducted by the national center for health statistics (nchs) of the u.s.
Melinta Therapeutics, Inc.

Systems and methods for averting overweight aircraft landing circumstances

The present disclosure includes a method, article of manufacture, and system for averting an overweight landing of an aircraft having a maximum landing weight (mlw). The method, article, and system may comprise, mutatis mutandis, determining a flight plan, receiving sensor data, determining, in response to the sensor data, that a predetermined event has occurred, receiving, in response to the predetermined event, an updated destination, computing, aircraft weight at the updated destination (wad), comparing the wad to the mlw, and/or generating, in response to the sensor data, an updated flight plan when the wad exceeds the mlw..
Honeywell International Inc.

Combination therapy with sglt-2 inhibitors and their pharmaceutical compositions

The present invention is directed to a pharmaceutical composition comprised of one or more sglt-2 inhibitor compound(s) in combination with one or more therapeutic agents which is suitable for the treatment of metabolic disorders including type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance, hyperglycemia, postprandial hyperglycemia, overweight, obesity, including class i obesity, class ii obesity, class iii obesity, visceral obesity and abdominal obesity, and metabolic syndrome.. .
Boehringer Ingelheim International Gmbh

Composition comprising at least one alginate for use in treatment and/or prevention of overweight

The present invention relates to a composition in the form of a powder or a viscous paste, and which includes at least one low viscosity alginate having a viscosity of less than about 100 mpas in a 1 wt % aqueous solution, and at least one high viscosity alginate having a viscosity of more than about 100 mpas in a 1 wt % aqueous solution. The composition can also include at least one suspending agent.
S-biotek Af 15. Marts 2006 1 Aps

Noninvasive facilitating weight loss

In accordance with one embodiment, an apparatus and method for facilitating weight loss are provided which constitute improvements over prior surgical treatments by providing a proven way to promote desirable weight loss in overweight patients through induced appetite reduction. The invention is comfortable enough to be used everyday without causing undue agitation to the wearer and provides measurable reductions in appetite and increased weight loss..

Methods for treating overweight or obesity

The present invention relates to methods of managing weight, and treating overweight or obesity and treating or preventing diabetes in a subject in need thereof. In one embodiment, the method comprises the steps of (a) orally administering to the subject from about 0.7 g to about 4 g of crosslinked carboxymethylcellulose; and (b) orally administering to the subject at least about 100 ml of water per gram of crosslinked carboxymethylcellulose.
Gelesis, Llc

Compositions and methods for weight loss in at risk patient populations

The present disclosure relates to compositions, kits, uses, systems and methods related to naltrexone plus bupropion for treating an overweight or obese subject at increased risk of adverse cardiovascular outcomes. Preferably, the subject has had type-two diabetes for a period of less than 6 years or is a current smoker, optionally that does not have type-two diabetes..
Orexigen Therapeutics, Inc.



Overweight topics:
  • Overweight
  • Metabolic Syndrome
  • C Syndrome
  • Weight Loss
  • Body Weight
  • Syndrome X
  • Nonalcoholic Steatohepatitis
  • Polypeptide
  • Steatohepatitis
  • Alcoholic Fatty Liver
  • Dyslipidemia
  • Metabolic Syndrome X
  • Fatty Liver
  • Amenorrhea
  • Liver Disease


  • Follow us on Twitter
    twitter icon@FreshPatents

    ###

    This listing is a sample listing of patent applications related to Overweight for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Overweight with additional patents listed. Browse our RSS directory or Search for other possible listings.


    0.3317

    file did exist - 2355

    1 - 1 - 51